Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Reagent case for predicting action effect of angiotensin conversion enzyme inhibitor medicament

A converting enzyme inhibitor, angiotensin technology, applied in the field of test kits, can solve problems such as affecting the curative effect, and achieve the effects of reducing medical costs and controlling blood pressure

Active Publication Date: 2007-10-31
SHENZHEN AUSA PHARM CO LTD +1
View PDF0 Cites 37 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In view of the important regulatory role of PRCP on the RAAS system and blood pressure, this functional single nucleotide polymorphism site is likely to affect the efficacy of ACEI drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Reagent case for predicting action effect of angiotensin conversion enzyme inhibitor medicament
  • Reagent case for predicting action effect of angiotensin conversion enzyme inhibitor medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Embodiment 1: kit (1) and implementation method thereof (based on PCR-RFLP detection method)

[0071] A test kit for predicting the antihypertensive effect of AECI drugs, consisting of the following components:

[0072] (1) Red blood cell lysate: NH 4 Cl, KHCO 3 , EDTA;

[0073] (2) White blood cell lysate: proteinase K, RNase A, NaCl, Tris, EDTA, SDS;

[0074] (3) Protein precipitation solution: 7.5M ammonium acetate (pH7.4)

[0075] (4) Nucleic acid storage solution: 1M tris-hydrochloric acid (Tris-HCl, pH8.0);

[0076] (5) PCR reaction mixture: 1.0ml [100mM Tris-HCl, 100mM KCl, pH8.3 (20°C)]; 5.0μMgCl 2 ; Each 0.4mM dATP, dCTP, dGTP, dTTP, prepared in sterile double distilled water, pH7.0; PCRP gene polymorphic site genotype detection primers;

[0077] (6) Taq DNA polymerase (5U / μl): storage buffer: 20mM Tris-HCl (pH8.0), 100mM KCl, 0.1mM EDTA, 1mM DTT, 0.5% NP40, 0.5% (v / v) Tween 20 , 50% glycerin;

[0078] (7) Positive plasmid: a whole blood sample of an in...

Embodiment 2

[0108] Embodiment 2: kit (2) and implementation method thereof (based on Taqman method)

[0109] A kit for predicting the risk of preeclampsia in pregnancy, consisting of the following components:

[0110] (1) Red blood cell lysate: containing NH 4 Cl, KHCO 3 , EDTA;

[0111] (2) White blood cell lysate: containing proteinase K, RNase A, NaCl, Tris, EDTA, SDS;

[0112] (3) Protein precipitation solution: 7.5M ammonium acetate (pH7.4)

[0113] (4) Nucleic acid storage solution: 1M tris-hydrochloric acid (Tris-HCl, pH8.0);

[0114] (5) PCR reaction mixture: Taq DNA polymerase and its reaction buffer; each 0.4mM dATP, dCTP, dGTP, dTTP;

[0115] (6) Polymorphic site genotype detection primers and Taqman probes of PRCP gene;

[0116] (7) Positive plasmid: a whole blood sample of an individual containing a polymorphic site heterozygous genotype of the PRCP gene, or a plasmid containing a polymorphic site heterozygous genotype of the PRCP gene;

[0117] (8) Negative control: d...

Embodiment 3

[0142] Example 3. Correlation analysis between the antihypertensive efficacy of benazepril and PRCP E112D polymorphism

[0143] In hypertensive patients, the lowering range of PRCP 112DD homozygous mutant type and 112ED heterozygous type was significantly weaker than that of 112EE homozygous wild-type patients, and the difference in systolic blood pressure lowering range was greater (Table 1). After correcting and adjusting factors such as age, region, gender, occupation, alcohol and tobacco habits, education level, baseline blood pressure, and BMI, it was found that the PRCP 112DD homozygous mutant genotype and 112ED heterozygous genotype were significantly higher than the PRCP 112EE homozygous wild-type genotype. The systolic blood pressure decreased by 8.61mmHg (95% CI: 4.51-10.71mmHg, p<0.001); the diastolic blood pressure decreased by 6.10mmHg (95%CI: 4.60- 7.60 mmHg, p<0.001). The results suggest that the E112D (Glu112Asp) polymorphism of the proline carboxypeptidase ge...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an agent box, which is characterized by the following: utilizing the relation between mononucleotide polymorphism site E112D genetype of important enzyme praline carboxypeptidase gene on vessel or esoderma regulating access and ACEI medical effect; forecasting ACEI medical effect; possessing good ACEI medical effect when genetype as 112EE pure wild-type; possessing bad effect when the genetype as 112ED heterozygous type or 112DD pure saltant; incorporating polymorphism parting oligonucleotide of E112D polymorphism site genetype with praline carboxypeptidase gene to test biological sample and related agent. This invention improves effectiveness and safety of clinic medicine, which provides criterion for new medicine of high blood pressure.

Description

technical field [0001] The invention relates to a method for predicting the action effect of drugs containing angiotensin-converting enzyme inhibitors by measuring the single nucleotide polymorphism (SNP) of an important enzyme gene on the regulation of blood vessel and endothelial function and angiotensin II degradation pathway Reagent test kit. It belongs to the field of medicine. Background technique [0002] Hypertension is one of the most common chronic diseases in my country and the world. There are about 690 million people in the world with hypertension, and the incidence rate is as high as 31.3%. Epidemiological studies have shown that blood pressure levels are linearly correlated with the incidence of cardiovascular disease; elevated blood pressure is an independent risk factor for stroke and coronary heart disease. Hypertension is the main cause of life-threatening heart and cerebrovascular diseases such as myocardial infarction, stroke, and renal insufficiency....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68
Inventor 邢厚恂张岩王滨燕李志平吴涤臧桐华徐希平
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com